文献速递骨软组织肉瘤与黑色素瘤

全球转移性黑色素瘤创新药物可及性:黑色素瘤世界学会与欧洲皮肤肿瘤协会在34个国家的调查

Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries.
PubMed 文献 · Eur J Cancer · 2018-10-31

黑色素瘤世界学会与欧洲皮肤肿瘤协会于2017年9月1日至2018年7月1日对34个国家专家进行网络调查,评估转移性黑色素瘤一线推荐治疗的可及性。估计13768例患者无法获得药物,BRAFi+MEKi和抗PD1免疫治疗在19/34和17/34国家全额报销,中位报销延迟991天,与ESMO MCBS评分、市场价格、人均卫生支出和Mackenbach评分显著相关。

要点

  • 估计34个受调查国家中有13768例转移性黑色素瘤患者无法获得创新药物。
  • BRAFi+MEKi联合方案在19/34(55.8%)国家全额报销,抗PD1免疫治疗在17/34(50%)国家全额报销。
  • 抗CTLA4+抗PD1联合方案仅在6/34(17.6%)国家全额报销,中位报销延迟为991天。

核心结论

  • 全球转移性黑色素瘤治疗存在巨大差异。
  • 创新药物可及性与经济参数及卫生系统绩效参数相关。
  • 迫切需要找到以患者为导向的药物开发、市场准入和报销路径。

研究设计与样本

  • 黑色素瘤世界学会与欧洲皮肤肿瘤协会于2017年9月1日至2018年7月1日开展网络调查,覆盖27个欧洲国家及美国、中国、澳大利亚、阿根廷、巴西、智利和墨西哥共34个国家的黑色素瘤专家,评估当前指南(美国国家综合癌症网络、欧洲肿瘤内科学会、欧洲癌症研究与治疗组织/欧洲皮肤肿瘤协会/欧洲皮肤病论坛)推荐的一线转移性黑色素瘤治疗可及性。
  • 收集药物许可与报销数据及治疗患者数量,并与人均卫生支出、Mackenbach卫生政策绩效评分、卫生技术评估、ASCO与ESMO临床获益量级量表(ESMO MCBS)评分及药品市场价格进行相关性分析。
  • 使用SPSS软件进行回归分析评估参数间的相关性。

主要发现

  • 受调查国家中估计有13768例患者无法获得药物。
  • 推荐的BRAFi+MEKi联合方案在19/34(55.8%)国家全额报销/覆盖,抗PD1免疫治疗在17/34(50%)国家全额报销/覆盖,抗CTLA4+抗PD1联合方案在6/34(17.6%)国家全额覆盖。
  • 中位报销延迟为991天,与ESMO MCBS评分(p = 0.02)、中位市场价格(p = 0.001)、人均卫生支出和Mackenbach评分(p < 0.01)显著相关。
  • 报销需要与国家主管部门进行价格谈判或签订管理准入协议(MEA)。

关键数值与推荐

  • BRAFi+MEKi联合方案在19/34(55.8%)国家全额报销/覆盖。
  • 抗PD1免疫治疗在17/34(50%)国家全额报销/覆盖。
  • 抗CTLA4+抗PD1联合方案在6/34(17.6%)国家全额覆盖。
  • 中位报销延迟为991天,与ESMO MCBS评分(p = 0.02)、中位市场价格(p = 0.001)、人均卫生支出和Mackenbach评分(p < 0.01)显著相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

According to data from recent studies from Europe, a large percentage of patients have restricted access to innovative medicines for metastatic melanoma. Melanoma World Society and European Association of Dermato-oncology conducted a Web-based survey on access to first-line recommended treatments for metastatic melanoma by current guidelines (National Comprehensive Center Network, European Society for Medical Oncology [ESMO] and European Organization for Research and Treatment of Cancer/European Association of Dermato-oncology/European dermatology Forum) among melanoma experts from 27 European countries, USA, China, Australia, Argentina, Brazil, Chile and Mexico from September 1st, 2017 to July 1st, 2018. Data on licencing and reimbursement of medicines and the number of patient treated were correlated with the data on health expenditure per capita (HEPC), Mackenbach score of health policy performance, health technology assessment (HTA), ASCO and ESMO Magnitude of clinical benefit scale (ESMO MCBS) scores of clinical benefit and market price of medicines. Regression analysis for evaluation of correlation between the parameters was carried out using SPSS software. The estimated number of patients without access in surveyed countries was 13768. The recommended BRAFi + MEKi combination and anti-PD1 immunotherapy were fully reimbursed/covered in 19 of 34 (55.8%) and 17 of 34 (50%) countries, and combination anti-CTLA4+anti-PD1 in was fully covered in 6 of 34 (17.6%) countries. Median delay in reimbursement was 991 days, and it was in significant correlation with ESMO MCBS (p = 0.02), median market price (p = 0.001), HEPC and Mackenbach scores (p < 0.01). Price negotiations or managed entry agreements (MEAs) with national authorities were necessary for reimbursement. In conclusion, great discrepancy exists in metastatic melanoma treatment globally. Access to innovative medicines is in correlation with economic parameters as well as with healthcare system performance parameters. Patient-oriented drug development, market access and reimbursement pathways must be urgently found.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Kandolf Sekulovic L, Guo J, Agarwala S, et al. Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries. Eur J Cancer. 2018. PMID: 30388700. doi:10.1016/j.ejca.2018.09.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。